The FDA approved Aqneursa, a treatment for ataxia-telangiectasia, marking a key regulatory milestone for a rare genetic disorder with limited options. The therapy comes from IntraBio, a privately held biotech, and the approval underscores the agency’s continued focus on accelerated pathways for serious rare diseases. For clinicians and developers, the approval provides a reference point for how the FDA is weighing benefit-risk in inherited immune and neurodegenerative conditions, where endpoints and duration of response are central. The accompanying coverage also highlighted additional company updates, but the headline event for the sector was the regulatory endorsement of a new rare-disease therapy.